Business Description
Biodexa Pharmaceuticals Plc
ISIN : GB00BNGF1L75
Description
Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.61 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -37.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -40.3 | |||||
| 3-Year EBITDA Growth Rate | 44.2 | |||||
| 3-Year FCF Growth Rate | 40.2 | |||||
| 3-Year Book Growth Rate | -67.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -86.9 | |||||
| 12-1 Month Momentum % | -92.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.18 | |||||
| Quick Ratio | 3.18 | |||||
| Cash Ratio | 2.29 | |||||
| Days Sales Outstanding | 569.23 | |||||
| Days Payable | 82.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -66.4 | |||||
| Shareholder Yield % | -169.21 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -835.54 | |||||
| Operating Margin % | -1776.56 | |||||
| Net Margin % | -1543.1 | |||||
| FCF Margin % | -1860.63 | |||||
| ROE % | -153.52 | |||||
| ROA % | -105.7 | |||||
| ROIC % | -548.3 | |||||
| ROC (Joel Greenblatt) % | -807.41 | |||||
| ROCE % | -153.88 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| PS Ratio | 0.42 | |||||
| PB Ratio | 0.71 | |||||
| Price-to-Tangible-Book | 0.71 | |||||
| EV-to-EBIT | 0.22 | |||||
| EV-to-EBITDA | 0.23 | |||||
| EV-to-Revenue | -3.7 | |||||
| EV-to-FCF | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 0.85 | |||||
| Price-to-Net-Cash | 1.42 | |||||
| Earnings Yield (Greenblatt) % | 454.55 | |||||
| FCF Yield % | -197.68 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers